coteauBeta Get App

CTY New listing

City Therapeutics, Inc.
IPO · listed Oct 16, 2026
$20.47
-1.47% Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-9%-6%-4%-1%+1%Oct 16Oct 23Oct 19
CTYSPY
1W
-8.6%
1M
–
3M
–
6M
–
YTD
–
1Y
–

Live chart

Loading live chart…

What they do

City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as retinal diseases and geographic atrophy.

Healthcare · Biotechnology

For information only · Important disclosures

Grades vs sector

No sector grades for CTY yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire · Oct 19
City Therapeutics (CTY) Debuts Strongly But Fair Value Remains Hard To Pin Down
Simply Wall St. · Oct 18
City Therapeutics (CTY) Filed A $239.1 Million Shelf Registration After Its IPO
Simply Wall St. · Oct 18
Another Biotech IPO Pops on Rough Day for Broader Market
Barrons.com · Oct 16
City Therapeutics surges in market debut after upsizing $200M IPO
Investing.com · Oct 16

Key stats

Market value$1.0B
52-week range$19.75 – $23.88
Revenue growth (latest quarter vs a year ago)+14.0%
Dividend yieldNo dividend
Valuation and fundamentals

Valuation & fundamentals

No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).

Earnings

CTY earningsNo upcoming date on file
Source: Yahoo Finance · refreshed 2026-10-24 02:54:16 ET
No EPS history available.

Stats refreshed 2026-10-24 02:54:16 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026